The global valsartan market is poised for strong and sustained expansion, with market valuation projected to rise from USD 1,545.78 million in 2025 to USD 3,184.29 million by 2035, registering a CAGR of 7.50% during the forecast period 2026–2035. The market is witnessing a transformative phase driven by increasing hypertension prevalence, rising cardiovascular disease burden, and the upcoming wave of generic cardiovascular therapies entering global markets.

Request of this Sample Report Here : – https://www.astuteanalytica.com/request-sample/valsartan-market

Key Market Highlights

• North America is anticipated to maintain its dominance by capturing nearly 38% of the global valsartan market share.
  
  • Asia-Pacific is projected to emerge as the fastest-growing regional market, expanding at a CAGR of approximately 8.2% between 2026 and 2035.
  
  • By product type, finished dosage forms (FDFs) accounted for around 62% of the overall market revenue in 2025.
  
  • Based on therapeutic delivery, monotherapy formulations continued to lead the industry with nearly 49.6% market share.
  
  • Among dosage categories, 81–160 mg formulations dominated with a substantial 46.4% share of global consumption.
  
  • Hypertension remained the leading indication, contributing approximately 53.7% of total market demand worldwide.
  
  • Retail pharmacies continued to serve as the primary distribution channel, accounting for nearly 47.1% of global patient transactions.

The valsartan industry is entering a new growth cycle fueled by major developments in the cardiovascular therapeutics landscape. One of the most significant catalysts is the July 2025 patent expiration of Novartis’ blockbuster therapy Entresto, which is expected to accelerate the adoption of generic sacubitril/valsartan formulations globally. Industry analysts anticipate a 12–15% surge in global valsartan API demand within the first year of generic launches, particularly across the United States, Europe, and emerging Asian pharmaceutical markets.

While conventional valsartan monotherapy products continue to generate stable revenues, future market value creation is increasingly shifting toward Fixed-Dose Combination (FDC) therapies. These combination formulations are forecast to contribute nearly 80% of total market value growth through 2030, supported by growing physician preference for combination treatments that improve medication adherence and clinical outcomes in hypertension and heart failure management.

Technological advancements in pharmaceutical manufacturing are also reshaping the competitive landscape of the valsartan market. Manufacturers are rapidly transitioning from conventional batch synthesis toward advanced continuous flow chemistry systems that improve production efficiency, enhance reaction control, and reduce impurity formation risks. These technologies can increase manufacturing yields by up to 8% while lowering operational costs and ensuring higher regulatory compliance.

In parallel, growing regulatory scrutiny surrounding nitrosamine contamination has accelerated the adoption of environmentally sustainable “green chemistry” practices. Pharmaceutical producers replacing Dimethylformamide (DMF) and similar solvents with safer alternatives are increasingly favored by premium buyers across regulated markets such as the United States and the European Union. As a result, manufacturers capable of delivering “clean-label” valsartan APIs are securing pricing premiums ranging from 5% to 10%.

Global Hypertension Burden Driving Long-Term Demand

The rising prevalence of hypertension remains the single largest demand driver for valsartan-based therapies. According to the World Health Organization (WHO), nearly 1.4 billion adults aged 30–79 years worldwide were living with hypertension in 2024, representing almost one-third of the global adult population within this age group. Despite growing awareness efforts, only around 23% of patients currently have their blood pressure adequately controlled, while approximately 44% remain undiagnosed.

This massive untreated and undertreated patient population continues to create significant long-term opportunities for antihypertensive medications, including valsartan and its combination therapies.

Valsartan Patient Population Trends

Millions of patients globally continue to rely on valsartan-based medications for hypertension and cardiovascular disease management.

• In the United States, prior to the 2018 NDMA contamination-related recalls, nearly 1.9 million patients were prescribed valsartan annually, generating approximately 9.2 million prescriptions.
  
  • Following the contamination crisis, prescription volumes declined sharply, falling to nearly 4.2 million prescriptions in 2019 as healthcare providers shifted patients toward alternative ARBs such as losartan.
  
  • Before the recall, valsartan represented approximately 18.4% of total ARB utilization in the United States, 16.3% in Canada, 3.1% in the United Kingdom, and nearly 1% in Denmark.
  
  • Globally, valsartan utilization declined by around 15.7% after the recall event; however, confidence in the drug has steadily recovered due to enhanced manufacturing standards and regulatory oversight.

Source: https://www.astuteanalytica.com/industry-report/valsartan-market

Looking ahead, the rapid commercialization of generic sacubitril/valsartan therapies is expected to significantly expand the global patient base using valsartan-containing medications through 2026 and beyond. Increasing adoption of cost-effective combination therapies, growing cardiovascular disease prevalence, and improved access to generic medicines in emerging economies are collectively expected to reinforce the market’s long-term growth trajectory.

Top Companies in the Valsartan Market

• Alembic Pharmaceuticals Limited


• AstraZeneca plc


• Aurobindo Pharma Limited


• Dr Reddy’s Laboratories Ltd.


• Glenmark Pharmaceuticals Inc.


• Hetero Labs Limited


• Lupin Pharmaceuticals Ltd.


• Mylan N.V.


• Novartis AG


• Others


• Sandoz International GmbH


• Sun Pharmaceutical Industries


• Teva Pharmaceutical Industries Ltd


• Torrent Pharmaceuticals Limited


• Zydus Cadila


• Other Prominent Players

Market Segmentation Overview

By Product Type

• Valsartan API


• Finished Dosage Forms (FDFs)

• 
  
  
  
  • Tablets
  
  
  
  

• 
  
  
  
  • Fixed-dose combinations
  
  
  
  

By Formulation

• Monotherapy Formulations


• Combination Formulations

By Dosage Strength

• ≤ 80 mg


• 81–160 mg


• > 160 mg

By Indication

• Hypertension


• Heart Failure


• Post-Myocardial Infarction


• Other Cardiovascular Conditions

By Distribution Channel

• Retail Pharmacies


• Hospital Pharmacies


• Online Pharmacies


• Other Channels

By Region

• North America

• 
  
  
  
  • The U.S.
  
  
  
  

• 
  
  
  
  • Canada
  
  
  
  

• 
  
  
  
  • Mexico
  
  
  
  

• Europe

• 
  
  
  
  • Western Europe
  
  
  
  

• 
  
  
  
  • 
    
    
    
    • The UK
    
    
    
    
  
  
  
  

• 
  
  
  
  • 
    
    
    
    • Germany
    
    
    
    
  
  
  
  

• 
  
  
  
  • 
    
    
    
    • France
    
    
    
    
  
  
  
  

• 
  
  
  
  • 
    
    
    
    • Italy
    
    
    
    
  
  
  
  

• 
  
  
  
  • 
    
    
    
    • Spain
    
    
    
    
  
  
  
  

• 
  
  
  
  • 
    
    
    
    • Rest of Western Europe
    
    
    
    
  
  
  
  

• 
  
  
  
  • Eastern Europe
  
  
  
  

• 
  
  
  
  • 
    
    
    
    • Poland
    
    
    
    
  
  
  
  

• 
  
  
  
  • 
    
    
    
    • Russia
    
    
    
    
  
  
  
  

• 
  
  
  
  • 
    
    
    
    • Rest of Eastern Europe
    
    
    
    
  
  
  
  

• Asia Pacific

• 
  
  
  
  • China
  
  
  
  

• 
  
  
  
  • India
  
  
  
  

• 
  
  
  
  • Japan
  
  
  
  

• 
  
  
  
  • Australia & New Zealand
  
  
  
  

• 
  
  
  
  • South Korea
  
  
  
  

• 
  
  
  
  • ASEAN
  
  
  
  

• 
  
  
  
  • Rest of Asia Pacific
  
  
  
  

• Middle East & Africa (MEA)

• 
  
  
  
  • Saudi Arabia
  
  
  
  

• 
  
  
  
  • South Africa
  
  
  
  

• 
  
  
  
  • UAE
  
  
  
  

• 
  
  
  
  • Rest of MEA
  
  
  
  

• South America

• 
  
  
  
  • Argentina
  
  
  
  

• 
  
  
  
  • Brazil
  
  
  
  

• 
  
  
  
  • Rest of South America
  
  
  
  

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭@- https://www.astuteanalytica.com/request-sample/valsartan-market

𝐀𝐛𝐨𝐮𝐭 𝐀𝐬𝐭𝐮𝐭𝐞 𝐀𝐧𝐚𝐥𝐲𝐭𝐢𝐜𝐚:

Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth, and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the globe.

They are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyse for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of the best cost-effective, value-added package from us, should you decide to engage with us.

Get in touch with us

Phone number: +18884296757

Email: [email protected]

Visit our website: https://www.astuteanalytica.com/